Hologic pacifies US Federal Trade Commission and sells Mammotest to Siemens
This article was originally published in Clinica
Executive Summary
Hologic is to sell all intellectual property relating to its Mammotest prone stereotactic bed breast biopsy systems (SBBS), which the company had recently acquired from Fischer Imaging, to diagnostic imaging rival Siemens Medical Solutions for $6.5m. The move followed a complaint filed last week by the US Federal Trade Commission (FTC), alleging that Hologic's acquisition of Fischer's prone SBBS business gave the former a monopoly in the US market for these devices.